This study will determine the titration regimen for SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Asian Chronic Kidney Disease patients on hemodialysis

Inclusion criteria

• Men or women of at least 18 years old or 20 years old in Japan.
• Stable maintenance of hemodialysis 3 times per week.
• Controlled serum phosphate if under phosphate-binder therapy.
• Serum phosphate level > 6.0 mg/dL (> 1.9 mmol/L) prior to study treatment initiation.

Exclusion criteria

• Peritoneal dialysis or a non-conventional hemodialysis technique .
• Parathyroidectomy or transplant scheduled during the study.
• Uncontrolled hyperparathyroidism
• History of hemochromatosis or ferritin > 800 µg/L.
• Clinically significant GI disorder
• Unstable medical condition other than Chronic Kidney Disease.
• Treated with sevelamer HCl monotherapy or SBR759.
• Treated with oral iron.
• Other protocol-defined inclusion/exclusion criteria may apply.